Digital Commons Network^™

Promoting Data Harmonization To Evaluate Vaccine Hesitancy In Lmics: Approach And Applications, Ryan Rego, Yuri Zhukov, Kyrani Reneau, Amy Pienta, Kristina L. Rice, Patrick Brady, Geoffrey Siwo, Peninah Wachira, Amina Abubakar, Ken Kollman

Institute for Human Development

Background: Factors influencing the health of populations are subjects of interdisciplinary study. However, datasets relevant to public health often lack interdisciplinary breath. It is difficult to combine data on health outcomes with datasets on potentially important contextual factors, like political violence or development, due to incompatible levels of geographic support; differing data formats and structures; differences in sampling procedures and wording; and the stability of temporal trends. We present a computational package to combine spatially misaligned datasets, and provide an illustrative analysis of multi-dimensional factors in health outcomes.

Methods: We rely on a new software toolkit, Sub-National Geospatial Data Archive …

Institute For Global Health And Development : Issue 5 - July 2023, Institute For Global Health And Development

IGHD Newsletter

• Research Highlights
• Key Publications
• IGHD in the News
• Webinars, Academics & Conferences
• ‘Choice’ Programme - Technical Advisory Group
• Welcome New Team Members
• Mark your Calendars: Upcoming Event
• Congratulations Team IGHD
• Collaborate With Us

Institute For Global Health And Development : Issue 4 - July - Sept 2022, Institute For Global Health And Development

IGHD Newsletter

• Research Highlights
• Key Publications
• News
• Reflections from IGHD’s Associate Faculty
• Reflections from IGHD’s Summer Interns
• Webinars and Dialogues
• Mark your Calendars: Upcoming Event
• Obituary
• Collaborate With Us

Tocilizumab And Covid-19: A Meta-Analysis Of 2120 Patients With Severe Disease And Implications For Clinical Trial Methodologies, Azza Sarfraz, Zouina Sarfraz, Muzna Sarfraz, Hinna Aftab, Zainab Pervaiz

Department of Paediatrics and Child Health

Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.
Materials and methods: A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials.
Results: A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, …